A Phase 1 interventional study of rhPSMA-7.3 (18F) Injection in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 1 site in Finland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 3 in phase 1, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
University of Florida · Sites in United States
Ages 18–100 · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18–90 · Men only
Hackensack Meridian Health · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2019.
This study's enrollment of 24 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 70 across the 15 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
13 studies in Prostatic Neoplasms by Bracco: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Prostatic Neoplasms by Bracco, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1, and was the 7th registered.
Bracco’s Prostatic Neoplasms studies by the year they started, since 2009.
1 of the studies testing flotufolastat F 18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285057Icahn School of Medicine at Mount SinaiDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, from their registry updates:
Among Bracco’s 13 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer.
Key Inclusion Criteria: Healthy Volunteers
Key Exclusion Criteria: Healthy Volunteers
Key Inclusion Criteria: Patients
Key Exclusion Criteria: Patients
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Drug: rhPSMA-7.3 (18F) Injection
Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Drug: rhPSMA-7.3 (18F) Injection
Radioligand for PET CT scanning
Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA
Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period, and changes in serum biochemistry, hematology, coagulation, urinalysis, vital signs, Electrocardiogram (ECG), injection site status, and physical examination findings.
Time frame: 1 month
This study was conducted between 11 June 2019 (first subject, screening visit) and 16 April 2020 (last subject, last visit) at a single site in Finland. Of the 24 potential subjects screened, 16 met all the study eligibility criteria (six healthy volunteers and 10 subjects with prostate cancer). Five subjects were considered screen failures and three subjects were not assigned to IMP as they were back-up subjects who were subsequently not required for PET imaging.
| Milestone | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C |
|---|---|---|---|---|
| Started | 6 | 3 | 3 | 4 |
| Completed | 6 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period, and changes in serum biochemistry, hematology, coagulation, urinalysis, vital signs, Electrocardiogram (ECG), injection site status, and physical examination findings.
| Participants | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA | 2 | 2 | 1 | 2 |
Collected over As specified in the Statistical Analysis Plan, results are presented as only those treatment-emergent adverse events which occurred up to 1 Month after the 18F administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Volunteers | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Prostate Cancer Cohort A | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) |
| Prostate Cancer Cohort B | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Prostate Cancer Cohort C | 0/4 (0%) | 1/4 (25%) | 1/4 (25%) |
| Event | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C |
|---|---|---|---|---|
| Retention of urineRenal and urinary disorders | 0/6 | 1/3 | 0/3 | 0/4 |
| Neutropenic infectionInfections and infestations | 0/6 | 0/3 | 0/3 | 1/4 |
| Event | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 1/3 | 0/3 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 0/6 | 0/3 | 1/3 | 0/4 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/3 | 0/3 | 1/4 |
| DizzinessNervous system disorders | 1/6 | 0/3 | 0/3 | 0/4 |
| SinusitisInfections and infestations | 1/6 | 0/3 | 0/3 | 0/4 |
| Hepatic lesionHepatobiliary disorders | 1/6 | 0/3 | 0/3 | 0/4 |
| Age, Continuous(Years) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Median | 62 (25 to 64) | 55 (55 to 56) | 69 (67 to 80) | 73 (65 to 76) | 64 (25 to 80) |
| Sex: Female, Male(Participants) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 4 | 13 |
| Male | 3 | 0 | 0 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 3 | 3 | 4 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Finland | 6 | 3 | 3 | 4 | 16 |
| Height (cm(Centimeters (cm)) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Median | 175.25 (160 to 186) | 177.50 (172 to 180) | 174 (172 to 176.5) | 171.75 (160 to 184) | 173.27 (160 to 186) |
| Weight (kg)(Kilograms (kg)) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Median | 79.15 (66.5 to 89.8) | 81.80 (71.0 to 87.5) | 82.70 (75.5 to 83.5) | 79.40 (77.5 to 99.0) | 80.50 (66.5 to 99.0) |
| Body Mass Index (kg/m2)(Kilograms/meters squared [kg^m2]) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| Median | 25.25 (23.2 to 30.0) | 27.70 (21.8 to 27.8) | 26.50 (25.5 to 27.6) | 28.45 (26.0 to 30.4) | 27.05 (21.8 to 30.4) |
| Eastern Cooperative Oncology Group (ECOG)(participants) | Healthy Volunteers | Prostate Cancer Cohort A | Prostate Cancer Cohort B | Prostate Cancer Cohort C | Total |
|---|---|---|---|---|---|
| 0 | — | 3 | 3 | 2 | 8 |
| 1 | — | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Apr 2020, 10 months.
Results were first posted in Feb 2026, 5 years 9 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 10 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flotufolastat F 18